J Korean Ophthalmol Soc.  2023 Aug;64(8):688-693. 10.3341/jkos.2023.64.8.688.

Effects of Subconjunctival Bevacizumab Injection after Primary Pterygium Surgery

• Yoon E
• Park M
• Choi J

• KMID: 2544995
• DOI: http://doi.org/10.3341/jkos.2023.64.8.688

Abstract

Purpose
This study evaluated the efficacy and safety of subconjunctival bevacizumab injection after primary pterygium surgery.
Methods
We performed a conjunctivo-limbal autograft after pterygium resection in 136 eyes of 128 patients with primary pterygium between December 2019 and July 2021. A subconjunctival bevacizumab injection of 2.5 mg (0.1 mL) was administered in the bevacizumab group but not in the control group (54 eyes of 48 patients). We compared pterygium recurrence rates between the two groups at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery.
Results
Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed.
Conclusions
Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed.

Keyword

Bevacizumab, Pterygium